Pilot PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity (PARTUM)

September 8, 2023 updated by: University of Calgary

A Pilot Study Assessing the Feasibility of a Randomized Controlled Trial Evaluating Aspirin in Postpartum Women at Risk of Developing Venous Thromboembolism

The pilot PARTUM trial is a randomized, multicenter, placebo-controlled trial. Women who are at modest risk of VTE (as defined by the inclusion criteria) will be identified during pregnancy, labor and delivery and up to 48 hours postpartum. Eligible and consenting participants will be randomly assigned to one of two study arms: aspirin 81 mg daily or placebo daily for 6 weeks.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

The purpose of the pilot PARTUM trial is to determine whether it is feasible to conduct a larger randomized controlled trial to determine whether low-dose aspirin is efficacious and safe at preventing postpartum venous thromboembolism (VTE) in women at increased risk of VTE, compared to placebo.

Given the large sample size needed to adequately power a large multicenter trial that assesses the efficacy of aspirin 81 mg versus placebo, the investigators first need to determine if it is possible to recruit enough women. If the pilot trial is successful and there are no major changes to the study design, then the secondary clinical outcomes collected in the pilot trial will be used in the analysis of the full multicenter trial.

Study Type

Interventional

Enrollment (Actual)

257

Phase

  • Early Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Alberta
      • Calgary, Alberta, Canada, T2N 2T9
        • Foothills Medical Centre
    • British Columbia
      • Vancouver, British Columbia, Canada, V6H 3N1
        • British Columbia Women's Hospital & Health Centre
    • Ontario
      • Ottawa, Ontario, Canada, K1H 8L6
        • The Ottawa Hospital - General Campus
      • Toronto, Ontario, Canada, M5G 1Z5
        • Mount Sinai Hospital
    • Loire
      • Saint-Étienne, Loire, France, 42270
        • Centre Hospitalier Universitaire de Saint-Etienne
      • Dublin, Ireland, D01 P5W9
        • Rotunda Hospital
    • North Holland
      • Amsterdam, North Holland, Netherlands, 1105
        • The Amsterdam Medical Centre

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria: Study inclusion criteria includes one (or more) first order criterion or two (or more) second order criteria. A patient is still eligible if they have multiple criteria met, at the discretion of the local investigator.

ONE (or more) First Order Criteria:

  1. Known inherited thrombophilia diagnosed prior to enrolment:

    i) Heterozygous factor V Leiden, OR ii) Heterozygous prothrombin gene variant, OR iii) Protein C deficiency, OR iv) Protein S deficiency

  2. Immobilization (90% of waking hours spent in bed) for ≥7 days anytime during the antepartum period

TWO (or more) Second Order Criteria:

  1. Postpartum infection
  2. Postpartum hemorrhage (>1000 mL of blood loss, regardless of delivery mode)
  3. Pre-pregnancy BMI ≥30 kg/m2
  4. Emergency or unplanned cesarean delivery
  5. Smoking ≥5 cigarettes/day before pregnancy
  6. Pre-eclampsia
  7. Current pregnancy ending in stillbirth (pregnancy loss >20 weeks gestation)
  8. Small-for-gestational-age infant (<3rd percentile adjusted for gestational age and sex).
  9. Previous history of superficial vein thrombosis

Exclusion Criteria:

  1. More than 48 hours since delivery
  2. Received more than 2 doses of low-molecular-weight heparin (LMWH) since delivery
  3. Need for postpartum LMWH prophylaxis or systemic anticoagulation as judged by the local investigator. May include but is not limited to:

    1. Documented history of provoked or unprovoked VTE
    2. Mechanical heart valve(s)
    3. Known antiphospholipid syndrome
    4. Known high-risk inherited thrombophilia i) Antithrombin deficiency; ii) Homozygous factor V Leiden; iii) Homozygous prothrombin gene mutation; iv) Compound heterozygosity factor V Leiden and prothrombin gene mutation; v) More than one inherited thrombophilia
  4. Need for postpartum aspirin as judged by the local investigator. May include but is not limited to:

    1. Documented history of myocardial infarction
    2. Documented history of ischemic stroke or transient ischemic attack (TIA)
  5. Contraindication to aspirin including:

    1. History of known aspirin allergy
    2. Documented history of a gastrointestinal ulcer
    3. Known platelet count <50 x 109/L at any time during the current pregnancy or postpartum
    4. Active bleeding at any site, excluding normal vaginal bleeding, at the time of randomization
    5. Most recent known hemoglobin ≤70 g/L documented during the current pregnancy or postpartum
    6. Known severe hypertension (SBP >200mm/hg and/or DBP >120mm/hg) during the current pregnancy or postpartum
  6. <18 years of age
  7. Unable or refused consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Aspirin
Aspirin 81 mg daily for six weeks post-randomization (postpartum)
Aspirin 81 mg p.o. daily
Other Names:
  • ASA
  • acetylsalicylic acid
Placebo Comparator: Placebo
Placebo daily for six weeks post-randomization (postpartum)
Placebo p.o. daily

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Recruitment Rate
Time Frame: 6 months
Mean recruitment rate per center per month
6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Consent Rate
Time Frame: 6 months
Proportion of eligible subjects who provide consent
6 months
Withdrawals/Loss to Follow-up
Time Frame: 9 months
Proportion of withdrawals/loss to follow-up among participants
9 months
Study Drug Compliance
Time Frame: 6 months
Level of compliance with study drug through participant recall and medication diary
6 months
Time Required to Obtain Site Institutional Approvals
Time Frame: 24 months
Proportion of sites requiring >18 months to obtain all required approvals/contracts from time of delivery of all study documents.
24 months
VTE Event Rate
Time Frame: 6 months
A more precise estimate of the VTE event rate
6 months
Bleeding Event Rate
Time Frame: 6 months
A more precise estimate of the major and clinically relevant non-major bleeding event rate
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Marc Rodger, MD, McGill University Health Centre/Research Institute of the McGill University Health Centre
  • Principal Investigator: Leslie Skeith, MD, University of Calgary

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 7, 2020

Primary Completion (Actual)

September 5, 2023

Study Completion (Actual)

September 5, 2023

Study Registration Dates

First Submitted

November 4, 2019

First Submitted That Met QC Criteria

November 4, 2019

First Posted (Actual)

November 6, 2019

Study Record Updates

Last Update Posted (Actual)

September 13, 2023

Last Update Submitted That Met QC Criteria

September 8, 2023

Last Verified

September 1, 2023

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Aspirin

Clinical Trials on Aspirin 81 mg

3
Subscribe